ABCIXIMAB

Abciximab is a glycoprotein IIb/IIIa inhibitor used as an antiplatelet medication. It prevents platelets from aggregating, which is crucial in the treatment of acute coronary syndrome and during percutaneous coronary interventions (PCI).

Indications

-Acute coronary syndrome (ACS) including unstable angina and myocardial infarction -Percutaneous coronary intervention (PCI) to prevent thrombus formation

Dosage

-For ACS: Typically administered as a bolus of 0.25 mg/kg IV, followed by a continuous infusion of 0.125 µg/kg/min for up to 12 hours. -For PCI: Administered as a bolus of 0.25 mg/kg IV just before the procedure, followed by a continuous infusion of 0.125 µg/kg/min for up to 12 hours.

Contra-Indications

-Active bleeding or bleeding disorders -Severe thrombocytopenia -Recent major surgery or trauma -History of intracranial hemorrhage -Severe uncontrolled hypertension

Special Precautions

-Monitor platelet counts regularly during therapy -Use with caution in patients with renal or hepatic impairment -Avoid concurrent use with other anticoagulants unless necessary

Side Effects

-Bleeding (including gastrointestinal and intracranial) -Thrombocytopenia -Hypotension -Allergic reactions (e.g., rash, fever)

Drug Interactions

-May interact with other antiplatelet agents (e.g., aspirin, clopidogrel) -Caution when used with anticoagulants like heparin -Potential interaction with medications affecting platelet function or coagulation